Overview

• Compound 3b functions as a β-lactamase inhibitor that blocks the KPC-2 enzyme from neutralizing Meropenem.
• Laboratory and animal model studies show the drug combination safely reduces Klebsiella pneumoniae load in lung infection experiments.
• The research findings were published in the Journal of Medicinal Chemistry following peer review.
• The study was led by Prof. Ranjana Pathania at IIT Roorkee in partnership with Prof. Annette Bayer’s team from UiT Tromsø.
• Investigators are now planning expanded preclinical trials and mapping clinical development to address antibiotic resistance.